Mylotarg is a medicine used to treat a blood cancer called acute myeloid leukaemia (AML) in patients aged 15 years and above who are newly diagnosed and have not tried other treatments. It is used in combination with daunorubicin and cytarabine (other cancer medicines). Mylotarg is used in patients with a protein called CD33 on their cancer cells (which is the case in most patients with AML). It is not used for a type of AML called acute promyelocytic leukaemia (APL). AML is rare, and Mylotarg was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 October 2000\. Mylotarg contains the active substance gemtuzumab ozogamicin.
Therapeutic Indication
Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33\-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).
Therapeutic Area (MeSH)
ATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Mylotarg
Medicine Name
Mylotarg
Aliases
N/ANo risk management plan link.
